Construction Of A Risk Model For LGGs Using Pattern Recognition Receptor Pathway-associated Genes

Pattern recognition receptors(PRRs)are widely expressed in the tumor microenvironment and are closely associated with tumor behavior.Exploration into differences in downstream gene expression of pattern recognition receptors may help to further stratify patients with lower grade gliomas(LGGs).So in the present study,based on expression profiles of 178 pattern recognition receptor pathway-related genes in the TCGA&CGGA datasets,we identified 3 distinguish clusters using consensus clustering method.And distinguish prognosis and biological process are observed among different clusters,which suggest a significant heterogeneity of PRRs activation in LGGs.So next,based on the PRRs pathway associated genes,a 5-gene risk model of LGGs is constructed using uni-variate Cox regression and least absolute shrinkage and selection operator(LASSO)regression.Kaplan-Meier analysis showed that the 5-gene risk signature is capable of distinguishing prognosis of high-and low-risk in both TCGA and CGGA datasets.In addition,multivariate Cox regression analysis and ROC curve indicates that the risk signature is an independent prognostic factor for LGGs and has robust predictive ability.Further external validation using the CGGA data showed consistent results with the above.Gene set enrichment analysis(GSEA)showed that the risk-signature defined high-risk LGGs group is enriched with inflammation,glycolysis,lymphocyte function inhibition,etc.Further more,the high-and low-risk groups also had significant differences in immune infiltration status,B7 family expression,and major treatment outcomes.In the present research,we revealed the heterogeneity of pattern recognition receptor pathways activation among patients with LGGs and constructed a 5-gene risk signature with robust prognostic power based on PRR pathway-associated genes,which should provide a new perspective to stratify LGGs patients and to assist decision-making on treatment strategies for patients with low-grade glioma.